Genetic Signatures Ltd. (AU:GSS)
ASX:GSS
Want to see AU:GSS full AI Analyst Report?
Top Page
Genetic Signatures Ltd.
(Sydney:GSS)
Select Model
Select Model
Rating:39Underperform
Price Target:
AU$0.08
▼(-68.75% Downside)
Action:Downgraded
Date:05/02/26
The score is driven primarily by weak financial performance—ongoing losses and negative cash flows outweigh the benefit of low leverage. Technicals also pressure the score, with the stock trading below all major moving averages and weak momentum. Valuation is further constrained by a negative P/E and no dividend yield provided.
Positive Factors
Proprietary assay technology
Genetic Signatures' proprietary 3base multiplex real-time PCR platform is a durable competitive asset. Multiplex capability lets labs test many pathogens from one sample, creating product differentiation, higher assay stickiness, and technical barriers that support long-term commercial adoption and R&D leverage.
Negative Factors
Persistent losses and negative cash flow
Sustained net losses and negative operating and free cash flows materially weaken long-term viability unless reversed. Continued cash burn compels external funding, dilutes equity or limits investment in sales, manufacturing scale and regulatory approvals, constraining durable growth prospects.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary assay technology
Genetic Signatures' proprietary 3base multiplex real-time PCR platform is a durable competitive asset. Multiplex capability lets labs test many pathogens from one sample, creating product differentiation, higher assay stickiness, and technical barriers that support long-term commercial adoption and R&D leverage.
Read all positive factors
Genetic Signatures Ltd. (GSS) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$17.94M
Dividend YieldN/A
Average Volume (3M)149.45K
Price to Earnings (P/E)―
Beta (1Y)0.91
Revenue Growth9.69%
EPS Growth52.31%
CountryAU
Employees117
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.05
Shares Outstanding227,138,820
10 Day Avg. Volume161,537
30 Day Avg. Volume149,454
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)1.65
Price to Sales (P/S)5.20
P/FCF Ratio-6.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.10Price Target Upside-58.33% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.08
Revenue Forecast (FY)AU$18.20M
Genetic Signatures Ltd. Business Overview & Revenue Model
Company Description
Genetic Signatures Limited operates as a molecular diagnostic (MDx) company in Australia, the Asia Pacific, the Americas, Europe, the Middle East, Israel, and Africa. It designs and manufactures a suite of real-time polymerase chain reaction-based...
How the Company Makes Money
GSS makes money primarily by selling molecular diagnostic test kits/assays that laboratories run on their PCR platforms, with revenue recognized from the supply of these consumable products as customers perform ongoing patient testing. A key reven...
Genetic Signatures Ltd. Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
45
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 16.08M | 15.90M | 9.77M | 16.94M | 35.42M | 28.28M |
| Gross Profit | -12.87M | 7.78M | 4.31M | -12.74M | 7.21M | 4.27M |
| EBITDA | -15.38M | -16.08M | -19.82M | -13.14M | 4.70M | 3.22M |
| Net Income | -11.27M | -20.10M | -17.86M | -14.05M | 3.06M | 1.76M |
Balance Sheet | ||||||
| Total Assets | 49.04M | 54.63M | 67.29M | 49.08M | 59.65M | 54.05M |
| Cash, Cash Equivalents and Short-Term Investments | 29.87M | 31.30M | 36.25M | 16.35M | 36.90M | 30.12M |
| Total Debt | 653.00K | 791.00K | 1.22M | 0.00 | 34.00K | 399.00K |
| Total Liabilities | 4.95M | 4.54M | 6.18M | 6.16M | 4.85M | 4.71M |
| Stockholders Equity | 44.09M | 50.09M | 61.10M | 42.91M | 54.80M | 49.34M |
Cash Flow | ||||||
| Free Cash Flow | -10.67M | -13.19M | -14.91M | -20.55M | 6.82M | -784.00K |
| Operating Cash Flow | -9.60M | -12.29M | -10.12M | -12.45M | 9.81M | 4.20M |
| Investing Cash Flow | -13.57M | -24.30M | -4.79M | -8.09M | -2.99M | -4.98M |
| Financing Cash Flow | -455.00K | 7.79M | 34.81M | -23.00K | -101.00K | -190.00K |
Genetic Signatures Ltd. Technical Analysis
Negative
0.24
Price Trends
0.10
Negative
0.13
Negative
0.21
Negative
Market Momentum
>-0.01
Positive
40.02
Neutral
44.59
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:GSS, the sentiment is Negative. The current price of 0.24 is above the 20-day moving average (MA) of 0.10, above the 50-day MA of 0.10, and above the 200-day MA of 0.21, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 40.02 is Neutral, neither overbought nor oversold. The STOCH value of 44.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:GSS.
Genetic Signatures Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | AU$48.81M | 10.72 | 72.82% | ― | 22.56% | 19.47% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$110.86M | -7.39 | -164.12% | ― | -14.85% | -41.04% | |
41 Neutral | AU$47.33M | -4.75 | -476.27% | ― | ― | -142.39% | |
40 Underperform | AU$28.39M | -2.45 | -164.22% | ― | ― | 26.04% | |
39 Underperform | AU$17.94M | -2.23 | -23.93% | ― | 9.69% | 52.31% | |
38 Underperform | AU$45.05M | -3.02 | -37.14% | ― | 4.66% | 12.39% |
* Healthcare Sector Average
AU:GSS
Genetic Signatures Ltd.
0.08
-0.51
-86.44%
AU:BDX
BCAL Diagnostics Limited
0.08
>-0.01
-2.50%
AU:RHY
Rhythm Biosciences Ltd.
0.14
0.07
117.74%
AU:LDX
Lumos Diagnostics Holdings Ltd.
0.13
0.10
316.67%
AU:CTE
Cryosite Limited
1.00
0.24
31.58%
AU:IIQ
Inoviq Ltd
0.34
-0.02
-5.56%
Genetic Signatures Ltd. Corporate Events
Genetic Signatures Announces Departure of Director Neil Gunn
May 8, 2026
Genetic Signatures Limited has announced that Dr Neil Gunn has ceased to be a director of the company as of 8 May 2026. At the time of his departure, Dr Gunn held 750,000 options as a registered holder, with no additional indirect interests or con...
Genetic Signatures Reshapes Board to Support Leaner Strategy
May 8, 2026
Genetic Signatures Limited has reorganised its board to streamline governance and sharpen its focus on strategic priorities, as the company transitions to a leaner, outsourced business model. The changes include Anne Lockwood ending her role as in...
Genetic Signatures Quantifies Revenue Impact of Danish Supply Deal
Apr 15, 2026
Genetic Signatures has detailed the expected impact of its newly announced Danish supply agreement with Hvidore, indicating that over a full year the contract should contribute around 6% of the company’s current sales. This estimate is based...
Genetic Signatures Sets Growth Path in Molecular Diagnostics for 1H FY26
Feb 25, 2026
Genetic Signatures Ltd., an ASX-listed molecular diagnostics firm headquartered in Sydney, focuses on PCR-based infectious disease testing using its proprietary 3base technology. The company serves pathology providers and hospitals with gastroente...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.